October 2008

Mark your calendar now for the contact lens event of the year. The International Contact Lens Summit, incorporating the CLAO Annual Meeting, will be held September 24 – 26, 2009, at the Hyatt Regency Hotel in Montreal, Canada. Many International speakers will be presenting cutting edge information in the field of contact lenses and anterior segment science. Exciting social events are currently being planned for Montreal, a city sometimes referred to as the “Paris of North America.” Additional information on the meeting and other meeting specifics will be updated on the CLAO Home Page at www.clao.org as it becomes available. You may also contact the CLAO Home Office via phone (877) 501-3937, fax (651) 731-0410, or email eyes@clao.org with any questions.

Thomas L. Steinemann, MD, a current member of the CLAO Board of Directors, will receive the 2008 Secretariat Award from the American Academy of Ophthalmology (AAO). This award “recognizes special contributions to the Academy and ophthalmology.” Dr. Steinemann was selected for the award for “years of serving as an Academy clinical correspondent.” Dr. Steinemann will be recognized in the AAO Annual Meeting Final Program and on the Academy’s web site. CLAO congratulates Dr. Steinemann on this well-deserved recognition.

Michael H. Goldstein, MD, has been elected Vice President of CLAO. Upon completion of this term, Dr. Goldstein will assume the position of President Elect. Thomas L. Steinemann has been elected to serve a second term as Director at Large. There are currently four Director at Large Positions on the CLAO Board of Directors. 

A search committee is now accepting CVs of qualified candidates for the executive vice president/chief executive officer position at the Academy to replace H. Dunbar Hoskins Jr., MD, who has announced he will retire March 31, 2009. The candidate must be a currently licensed, board-certified ophthalmologist, have past or present experience with the Academy as a committee or board member, have successful experience in leadership and management, and have extensive knowledge of the eye care industry and the issues confronting ophthalmologists. This position is based in San Francisco and requires extensive domestic and international travel. The full job description and application process can be foundhttp://www.aao.org/evp_job_description.cfm.  Additional information will be available to serious candidates.

Information in this section has been provided to CLAO by press releases and other means. CLAO does not warranty its accuracy nor does notice of a product in this section constitute an endorsement by CLAO. 

Bausch & Lomb, Inc., announced on August 18th that the company has hired two health industry veterans to lead its regional business operations, effective immediately. John H. Brown is named president, Europe, Middle East and Africa, and corporate vice president. David N. Edwards is named president, Asia Pacific, and corporate vice president. 

CooperVision announced on August 25th that the company has again expanded the parameters of its Biofinity™ silicone hydrogel contact lenses. The lenses are now available in a sphere power range of +8.00D to -12.00D. Biofinity monthly replacement silicone hydrogel lenses feature CooperVision’s unique Aquaform™ technology. The water content of Biofinity contact lenses is 48 percent, Dk is 128, and Dk/t is 160. The lenses also feature a base curve of 8.6mm and a diameter of 14.0mm. 

Novartis AG and Nestle S.A. announced on July 8 th that they have completed the first step purchase and sale of 74 million shares of Alcon, Inc. common stock currently owned by Nestle pursuant to the agreement dated April 6, 2008 between Novartis and Nestle. With the completion of the first step transaction, Nestle remains Alcon's majority shareholder with approximately 52% of Alcon's issued capital and Novartis now owns a minority stake in Alcon equal to approximately 24.85% of Alcon's issued capital. In addition to this minority investment, the April 6, 2008 agreement provides Novartis with a call option to purchase Nestle's remaining Alcon common shares. The agreement also provides Nestle with a put option to sell its remaining Alcon common shares to Novartis. These options commence on January 1, 2010, and expire on July 31, 2011. If either of these options are exercised, and subject to the agreement's closing conditions (including regulatory approval), Novartis would become the majority shareholder of Alcon with approximately 77% of its issued shares. 

Johnson & Johnson Vision Care, Inc., maker of ACUVUE® Brand Contact Lenses, announced on July 23rd the launch of its new professional website www.jnjvisioncare.com. The comprehensive, easy to navigate site is designed to provide doctors and staff with valuable resources and tools to help patients with their contact lens questions and advance physicians’ practices with product updates and practice management suggestions.


  • AAO Annual Meeting will be held November 8-11, 2008 in Atlanta, GA.
  • 2009 International Contact Lens Summit will be held September 24-26, 2009 in Montreal, Canada.

CLAO “DID YOU KNOW?” The first disposable soft contact lenses with an ultra-violet light absorber were made available in the U.S in 1996.